ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 4.01 USD 13.6% Market Closed
Market Cap: 496.8m USD

ADC Therapeutics SA
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ADC Therapeutics SA
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
ADC Therapeutics SA
NYSE:ADCT
Net Income (Common)
-$166.9m
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Net Income (Common)
-CHf71.9m
CAGR 3-Years
1%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Net Income (Common)
-$488.3m
CAGR 3-Years
10%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Net Income (Common)
CHf72.7m
CAGR 3-Years
340%
CAGR 5-Years
90%
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
Net Income (Common)
-CHf117.9m
CAGR 3-Years
49%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Net Income (Common)
-CHf7.1m
CAGR 3-Years
14%
CAGR 5-Years
10%
CAGR 10-Years
N/A
No Stocks Found

ADC Therapeutics SA
Glance View

Market Cap
451.6m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
4.54 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

What is ADC Therapeutics SA's Net Income (Common)?
Net Income (Common)
-166.9m USD

Based on the financial report for Sep 30, 2025, ADC Therapeutics SA's Net Income (Common) amounts to -166.9m USD.

What is ADC Therapeutics SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
6%

Over the last year, the Net Income (Common) growth was 55%.

Back to Top